5GH.F GUARDANT HEALTH CL. A
- Market cap
- EUR 19.1B
- P/E
- -
- P/B
- 53.66x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 5GH.F undervalued?
Graham numberThe Graham number of GUARDANT HEALTH CL. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GUARDANT HEALTH CL. A fundamental analysis
No fundamental analysis for GUARDANT HEALTH CL. A yet.
GUARDANT HEALTH CL. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GUARDANT HEALTH CL. A
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a …
Full company profileGUARDANT HEALTH CL. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GUARDANT HEALTH CL. A annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 374M | 450M | 564M | 739M | 982M | 1.33B |
| Gross Profit | 251M | 293M | 337M | 449M | 633M | 869M |
| Operating Income | -411M | -544M | -565M | -444M | -437M | -511M |
| EBITDA | - | -615M | -433M | -390M | -374M | -430M |
| Net Income | -406M | -655M | -479M | -436M | -416M | -475M |
| EPS | -3.99 | -6.38 | -3.94 | -3.52 | -3.19 | -3.53 |
| Balance Sheet | ||||||
| Total Assets | 2.20B | 1.61B | 1.79B | 1.49B | 2.01B | 1.89B |
| Total Liabilities | 1.56B | 1.55B | 1.63B | 1.63B | 2.11B | 2.16B |
| Shareholders' Equity | 645M | 60.2M | 159M | -140M | -99.3M | -276M |
| Cash & Short-term Investments | 492M | 142M | 1.13B | 526M | 378M | 1.03B |
| Cash Flow | ||||||
| Operating Cash Flow | -209M | -309M | -325M | -240M | -185M | -196M |
| Capital Expenditure | 75.0M | 77.5M | 20.5M | 35.1M | 48.3M | 41.1M |
| Free Cash Flow | -284M | -387M | -345M | -275M | -233M | -237M |
| Ratios | ||||||
| ROE | -62.9% | -1,087.7% | -302.1% | - | - | - |
| ROA | -18.4% | -40.7% | -26.8% | -29.4% | -20.7% | -25.2% |
| Net Profit Margin | -108.6% | -145.6% | -85.0% | -59.0% | -42.4% | -35.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GUARDANT HEALTH CL. A dividends
GUARDANT HEALTH CL. A has not paid dividends in the last 5 fiscal years.
Who owns GUARDANT HEALTH CL. A
- Insiders 3.95%
- Institutions 96.05%
- Public & others 0.00%
- Shares outstanding 135M
- Free float 131M
GUARDANT HEALTH CL. A company profile
- Company name
- GUARDANT HEALTH CL. A
- Ticker
- 5GH.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,490
- Fiscal year end
- December
- Address
- 3100 Hanover Street, Palo Alto, CA, United States, 94304
- Phone
- 855 698 8887
- Website
- guardanthealth.com
About GUARDANT HEALTH CL. A
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
GUARDANT HEALTH CL. A management
10- Dr. Helmy Eltoukhy Ph.D.Co-Founder, Co-CEO & Chairman · born 1979
- Mr. Michael BellChief Financial Officer · born 1969
- Dr. Darya ChudovaChief Technology Officer · born 1974
- Mr. John G. Saia J.D.Chief Legal Officer & Corporate Secretary · born 1973
- Mr. Andy AmentSenior Vice President of Operations
- Mr. Kumud KaliaChief Information Officer · born 1966
- Zarak KhurshidVice President of Investor Relations
- Ms. Gulshan Shaver J.D.Senior VP of Legal Affairs & Chief Compliance Officer
- Ms. Jennifer HigginsSenior Vice President of Public Affairs
- Mr. Stephen MurphySenior Vice President of Screening Marketing